Okada Presents Findings on Cancer Vaccine

San Francisco, CA, November 23, 2013 -- Hideho Okada, MD, PhD, professor of neurological surgery, surgery and immunology at the University of Pittsburgh and co-leader of the University of Pittsburgh Cancer Institute’s Brain Tumor Program, presented findings of a brain cancer vaccine at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in San Francisco this past weekend.

According to the study’s findings, the vaccine -- comprised of synthetic peptides and adjuvant poly:ICLC -- was determined to be well-tolerated and induced specific and sustained immune responses against its brain tumor targets. Further, patients with a high magnitude of immunologic responsiveness experienced prolonged progression free survival.

The synthetic peptide vaccine, developed by the University of Pittsburgh researchers, had previously demonstrated single-agent clinical efficacy, including complete responses, in Phase 1/2 trials in both adults and children with high-grade glioma (HGG), including glioblastoma multiforme (GBM).

The study was supported generously by the National Institutes of Health, the Musella Foundation for Brian Tumor Research and Information, as well as the Voices Against Brain Cancer (VABC) Foundation.